Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiarrhythmic medications Clear all
Active, not recruiting Phase 4 Interventional

Liraglutide Effect in Atrial Fibrillation

NCT03856632
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
Drug · Other · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Antiarrhythmic Effects of Spironolactone in Patients With ICDs

NCT04495712
View directory record Official record
Conditions
Ventricular Arrhythmias
Interventions
spironolactone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine Implantable Cardioverter-Defibrillator Trial

NCT01215253
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • East Palo Alto, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 30, 2026, 5:51 AM EDT
Not listed Phase 4 Interventional

Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)

NCT03228823
View directory record Official record
Conditions
Ventricular Premature Beats, Contractions, or Systoles, Cardiomyopathies
Interventions
Radiofrequency ablation, Amiodarone (Antiarrhythmic drug)
Procedure · Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 30, 2026, 5:51 AM EDT
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Phase 3 Interventional

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

NCT04037397
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 30, 2026, 5:51 AM EDT
Not listed No phase listed Observational

Genetics of QT Prolongation With Antiarrhythmics

NCT02439658
View directory record Official record
Conditions
Long QT Syndrome, Drug Toxicity
Interventions
Dofetilide and/or sotalol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

NCT01049009
View directory record Official record
Conditions
High Blood Pressure
Interventions
Nebivolol, Metoprolol XL
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 30, 2026, 5:51 AM EDT
Not listed Phase 4 Interventional

Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

NCT04160000
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Interventions
Catheter ablation, Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation, Insertion of CardioMems Hemodynamic monitor, Empiric heart failure drug therapy
Device · Drug
Lead sponsor
Electrophysiology Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Flagstaff, Arizona • Jonesboro, Arkansas • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 30, 2026, 5:51 AM EDT
Terminated Phase 3 Interventional Results available

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

NCT00589303
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Not applicable Interventional

Effects of Osteopathic Manipulative Therapy on Arrhythmias

NCT04004741
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
Osteopathic Manipulative Treatment, Light Touch Therapy
Procedure
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Head, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 30, 2026, 5:51 AM EDT
Terminated Phase 3 Interventional Results available

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

NCT04208997
View directory record Official record
Conditions
Tachycardia, Ventricular, Catheter Ablation
Interventions
Antiarrhythmic drug
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 30, 2026, 5:51 AM EDT
Not yet recruiting No phase listed Observational

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

NCT06783868
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Catheter Ablation, Market-approved AVNB, OAC and AAD
Device · Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 30, 2026, 5:51 AM EDT
Completed No phase listed Observational

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

NCT04128878
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Sotalol, Dofetilide
Drug
Lead sponsor
Samir Saba
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 30, 2026, 5:51 AM EDT
Completed No phase listed Observational

Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

NCT03376438
View directory record Official record
Conditions
Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Interventions
Prospective observational cohorts
Other
Lead sponsor
Edgar Jaeggi
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 30, 2026, 5:51 AM EDT
Terminated Not applicable Interventional

Initial Management of Patients Receiving a Single Shock (IMPRESS)

NCT03531502
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Ventricular Tachycardia Ablation, Standard Medical Therapy, Non-Invasive Programmed Stimulation (NIPS)
Procedure · Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 30, 2026, 5:51 AM EDT
Active, not recruiting Not applicable Interventional

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Sep 30, 2026, 5:51 AM EDT
Not listed Phase 3 Interventional

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

NCT01013714
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
Interventions
Cardiac Sympathetic Denervation (CSD), Routine Care
Procedure · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Phase 4 Interventional

Antiarrhythmics or Ablation for Ventricular Tachycardia 2

NCT02830360
View directory record Official record
Conditions
Ventricular Tachycardia (VT)
Interventions
Antiarrythmic Drug Therapy, Catheter ablation
Drug · Procedure
Lead sponsor
John Sapp
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Hartford, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 30, 2026, 5:51 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Acute Mechanical Response to Anti-arrhythmic Drug Therapy

NCT02575534
View directory record Official record
Conditions
Arrhythmias
Interventions
Procainamide
Drug
Lead sponsor
Evan Adelstein, MD
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 30, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

NCT00911508
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Left atrial ablation, Rate or Rhythm Control Therapy
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
76
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 30, 2026, 5:51 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

NCT04704050
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions
dronedarone 400 mg Oral Tablet, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 30, 2026, 5:51 AM EDT
Terminated Phase 4 Interventional Results available

Catheter Ablation vs. Medical Therapy in Congested Hearts With AF

NCT02686749
View directory record Official record
Conditions
Congestive Heart Failure, Left Ventricular Failure, Atrial Fibrillation
Interventions
Catheter Ablation, FDA approved anti arrhythmic drug
Device · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Hartford, Connecticut • Akron, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 30, 2026, 5:51 AM EDT